- Poster presentation
- Open Access
Complicated systemic JIA with macrophage activation syndrome and pulmonary hypertension responsive to a anti IL-1: case report
© Paim-Marques et al; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Pulmonary Artery Pressure
- Pericardial Effusion
Systemic juvenile idiopathic arthritis (SJIA) is characterized by fevers, rash, and chronic arthritis, and interleukin -1 (IL-1) and IL-6 inhibitors seems to be effective treatments. Pulmonary arterial hypertension (PAH) and macrophage activation syndrome (MAS), which is a unremitting fever, coagulopathy, pancytopenia, and multiple organ dysfunction. These complications can be fatal and may be the result of severe uncontrolled systemic disease activity or influenced by medication exposure.
Describe a 7 year old girl with systemic JIA complicated with macrophage activation syndrome and pulmonary arterial hypertension refractory to numerous treatments, with good response to canakinumab, IL-1 inhibitor.
Female patient was diagnosed with systemic JIA at seven year old. At eight years, was hospitalized with desease reactivation in use of cyclosporin and oral prednisone. An echocardiogram showed mild pericardial effusion and moderate PAH (69mmHg), ferritin:5.865mg/dL, triglycerides 428mg/dL, fever, splenomegaly and macrophage activity in bone marrow fulfilled the macrophage activation syndrome (MAS) criteria. Methylprednisolone pulse was started and echocardiographic control showed mild improvement. Anti IL-6 therapy (tocilizumab - 8mg/kg) was started every two weeks, total of 2 doses. Initially, there was clinical improvement and decrease in pulmonary artery pressure (PAP) to 38 mmHg. However, one week later, a new echocardiogram showed mild PH (44mmHg), new pericardial effusion and acute relapse of disease symptoms (fever, rash, adenophathy) and new MAS (ferritin 30.000mg/dl, triglycerides 500mg/dL). The patient underwent a new pulse methylprednisolone and oral prednisolone resulting in clinical improvement and after the second dose of tocilizumab, high transaminases levels were observed indicating anti-IL-6 suspension. After one month, she had a new clinical decompensation with signs of heart failure requiring intensive care. Echocardiogram showed PAP of 95mmHg. A new methylprednisolone pulse therapy was prescribed. After clinical stabilization, received the first dose of IL-1 inhibitor. Second dose of Canakimumabe was performed 4 weeks later, and, at this moment PAP was 48mmHg in absence of fever, rash, arthritis and reduced hepatosplenomegaly.
In the present case, the patient developed MAS and pulmonary hypertension and had important clinical improvement with anti IL-1 theraphy. MAS is thought to be an acquired form of hemophagocytic lymphohistiocytosis, the real incidence in systemic JIA is not known, but studies show that there are histological changes in the bone marrow, even without clinical symptoms in many patients. HP is a rare condition where immunosuppressants and biological agents may be involved. Diagnose is difficult, but we should have protocols to search it.
Systemic JIA can be complicated, among others, by MAS and pulmonary arterial hypertension (PAH). Further prospective studies are needed to determine the real factors associated with the development of pulmonary complications.
L Paim-Marques Paid Instructor for Novartis, Shire, L Landim: None declared, S Firmino: None declared, C Monteiro: None declared.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.